An Emergency Department Intervention to Increase Warfarin Use for Atrial Fibrillation

被引:3
作者
Skolarus, Lesli E. [1 ]
Morgenstern, Lewis B. [1 ,2 ,3 ]
Scott, Phillip A. [1 ,3 ]
Lisabeth, Lynda D. [1 ,2 ]
Murphy, Jillian B. [1 ]
Migda, Erin M. [1 ]
Brown, Devin L. [1 ]
机构
[1] Univ Michigan, Sch Publ Hlth, Stroke Program, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Sch Med Sch, Dept Emergency Med, Ann Arbor, MI 48109 USA
关键词
Atrial fibrillation; emergency department; health services research; stroke prevention; ANTITHROMBOTIC THERAPY; RISK-FACTORS; STROKE; PREVALENCE;
D O I
10.1016/j.jstrokecerebrovasdis.2012.11.005
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Emergency department (ED) encounters represent lost opportunities to facilitate anticoagulation for stroke prevention in atrial fibrillation (AF). However, screening of warfarin eligibility in the ED may not be feasible. We evaluated whether a practical quality improvement initiative increased postdischarge warfarin use in ED patients with AF. Methods: This quasiexperimental study was conducted in a single academic health system. Eligible subjects were consecutive patients with AF identified by electrocardiogram during an ED evaluation who were discharged from the ED or the subsequent hospitalization off warfarin. The study consisted of data collection during 2 time periods: (1) preintervention (October 2009 to April 2010), serving as a baseline, and (2) intervention (June 2010 to December 2010). The intervention consisted of a mailing to the subjects and their primary care physicians. The primary outcome was the proportion of subjects taking warfarin 1 month after ED presentation. Differences between the proportion of preintervention and intervention subjects taking warfarin and warfarin or aspirin were compared with Chi-square tests. Results: At 1 month, 111 of 204 (55%) of the eligible preintervention and 90 of 160 (56%) of the eligible intervention group patients participated. There was no difference between the preintervention and intervention groups in the proportion of subjects taking warfarin at 1 month (12% v 9%; P = .54) or the proportion of subjects taking either aspirin or warfarin at 1 month (72% v 75%; P = .59). Conclusions: This practical stroke prevention quality improvement initiative was not associated with an increase in warfarin use among ED patients with AF.
引用
收藏
页码:199 / 203
页数:5
相关论文
共 13 条
[1]   Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals [J].
Albers, GW ;
Yim, JM ;
Belew, KM ;
Bittar, N ;
Hattemer, CR ;
Phillips, BG ;
Kemp, S ;
Hall, EA ;
Morton, DJ ;
Vlasses, PH .
ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (20) :2311-2316
[2]   Optimizing the use of antithrombotic therapy for atrial fibrillation in older people: A pharmacist-led multidisciplinary intervention [J].
Bajorek, BV ;
Krass, I ;
Ogle, SJ ;
Duguid, MJ ;
Shenfield, GM .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2005, 53 (11) :1912-1920
[3]   Antithrombotic prescribing in atrial fibrillation: application of a prescribing indicator and multidisciplinary feedback to improve prescribing [J].
Elliott, RA ;
Woodward, MC ;
Oborne, CA .
AGE AND AGEING, 2002, 31 (05) :391-396
[4]   PREVALENCE, AGE DISTRIBUTION, AND GENDER OF PATIENTS WITH ATRIAL-FIBRILLATION - ANALYSIS AND IMPLICATIONS [J].
FEINBERG, WM ;
BLACKSHEAR, JL ;
LAUPACIS, A ;
KRONMAL, R ;
HART, RG .
ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (05) :469-473
[5]  
Frieden TR, 2011, NEW ENGL J MED, V365, DOI [10.1056/NEJMp1110421, 10.1056/NEJMP1110421]
[6]   Validation of clinical classification schemes for predicting stroke - Results from the national registry of Atrial Fibrillation [J].
Gage, BF ;
Waterman, AD ;
Shannon, W ;
Boechler, M ;
Rich, MW ;
Radford, MJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (22) :2864-2870
[7]   Prevalence of diagnosed atrial fibrillation in adults - National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study [J].
Go, AS ;
Hylek, EM ;
Phillips, KA ;
Chang, YC ;
Henault, LE ;
Selby, JV ;
Singer, DE .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (18) :2370-2375
[8]   Apixaban versus Warfarin in Patients with Atrial Fibrillation [J].
Granger, Christopher B. ;
Alexander, John H. ;
McMurray, John J. V. ;
Lopes, Renato D. ;
Hylek, Elaine M. ;
Hanna, Michael ;
Al-Khalidi, Hussein R. ;
Ansell, Jack ;
Atar, Dan ;
Avezum, Alvaro ;
Cecilia Bahit, M. ;
Diaz, Rafael ;
Easton, J. Donald ;
Ezekowitz, Justin A. ;
Flaker, Greg ;
Garcia, David ;
Geraldes, Margarida ;
Gersh, Bernard J. ;
Golitsyn, Sergey ;
Goto, Shinya ;
Hermosillo, Antonio G. ;
Hohnloser, Stefan H. ;
Horowitz, John ;
Mohan, Puneet ;
Jansky, Petr ;
Lewis, Basil S. ;
Luis Lopez-Sendon, Jose ;
Pais, Prem ;
Parkhomenko, Alexander ;
Verheugt, Freek W. A. ;
Zhu, Jun ;
Wallentin, Lars .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (11) :981-992
[9]   Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation [J].
Hart, Robert G. ;
Pearce, Lesly A. ;
Aguilar, Maria I. .
ANNALS OF INTERNAL MEDICINE, 2007, 146 (12) :857-867
[10]   Risk factors for stroke and thromboprophylaxis in atrial fibrillation:: What happens in daily clinical practice?: The GEFAUR-1 study [J].
Laguna, P ;
Martín, A ;
del Arco, C ;
Gargantilla, P .
ANNALS OF EMERGENCY MEDICINE, 2004, 44 (01) :3-11